The recent outbreak of the concept of "longevity medicine" NMN has caused shocks in the capital market. In mid-July, the "Internet celebrity longevity medicine" NMN concept stock became a dark horse in the market. The stocks of related companies have been closed one after another, and a listed company has gained 8 daily limits in 11 days.

The full name of NMN is nicotinamide mononucleotide, the English name is Nicotinamide Mononucleotide, which is the precursor of NAD+ and can be converted into NAD+ in the body. NAD participates in more than 500 biochemical reactions in the human body, providing energy and vitality to human cells. Animal and other related experimental studies have shown that NMN supplementation in middle-aged and elderly people can delay human aging.

In 2019, the global anti-aging market exceeded 190 billion US dollars. As a new type of anti-aging health care product, NMN has attracted widespread attention for its safety and effectiveness.

Syncozymes is one of the world's leading suppliers of NMN raw materials. Since 2009, Syncozymes has been researching the development and industrial production of NAD family products, including the development and production of NMN, NAD, NADH, NADP and other products. Syncozymes is the first company in China to realize the localization of NAD products.

In July 2020, Syncozymes's NMN raw material has passed the "acute oral toxicity test" of the authoritative organization, which further confirmed that the substance is safe and non-toxic.